Synthelis's Business Manager, Bruno Tillier, is responsible for the development and implementation of Synthelis's commercial strategies as well as other day-to-day operational duties in the fields of finance, sales & marketing, new product development etc. Bruno Tillier's post-thesis scientific career started as a researcher in Calgary, Canada, where he developed a transgenic model in animals for use in pre-clinical studies focussed on leukaemia and inflammatory auto-immune illnesses. As a Technology Transfer Manager at Floralis, the University Joseph Fourier's technology transfer subsidiary and one of France's leading universities for Lifesciences & Healthcare, he is responsible for overseeing the process that will turn Synthelis from a Business Unit, supported financially and juridicially by Floralis,into a company in its own right.
Remy Beroud's career has taken him full circle from a student at the Université Joseph Fourier (UJF), to Business Development Manager at Synthelis, whose commercial offering is centred around patented technologies originating from the UJF.
Remy is responsible for managing all commercial agreements with industry, from prospection through to contract validation. He also works in close partnership with Bruno Tillier, assisting him as required with other aspects of Synthelis's development.
Professor Jean Luc- Lenormand
After finishing his doctorate at the Institut Gustave Roussy, France, Jean-Luc Lenormand crossed the Atlantic for five years to work at the department of Chemistry/Biochemistry (University of San Diego) where he ran a project conducting research on the transduction pathways involved in the regulation of meosis in Xenopus. A move back to France saw him start work at the Institute of structural biology (CEA/CNRS) Grenoble, France where his principal responsibilities were focussed on a research project that looked at transduction pathways activated in response to gamma radiation of mammary cells (a joint project with the Sidney Kimmel Cancer Centre, San Diego). This was followed by a return to public sector research at the University Hospital Grenoble and a project centred on the development of new vectors for use in vaccines and therapies. Professor Lenormand won the renowned Marie Curie Excellence Grant for work that was carried out at this institution. 2005 saw a move to the Université Joseph Fourier's Humprother laboratory as Team Leader, a post that would result in the development of research in therapeutic vectors; as well as intellectual property that would eventually form the basis of the Synthelis offering.
Professor Don Martin
After completing postdoctoral training at Sydney University as the inaugural Medical Foundation Post-Doctoral Fellow (1988-91), Don established patch-clamp electrophysiology laboratories at St Vincent’s Hospital and the University of Technology, Sydney. He has published more than 80 scientific papers, a book published by Springer, and is an author on 4 patents. In 2008 he was awarded a Chaire d’Excellence in nanosciences by the French government and is appointed as a Professor at the Université Joseph Fourier in Grenoble. In 2008 the Irish government invited Don as an international evaluator for a new industry-led nanotechnology initiative. From 2003-2008 he was invited to speak on nanobiotechnology at The Biotechnology Industry Organisation (BIO) annual conferences. Prior to moving to Grenoble, Don was an Executive Board Member of the Australian French Association for Science and Technology (AFAS NSW).
Professor Emmanuel Drouet
Emmanuel Drouet (PharmD) is group leader in the UVHCI (Unit Virus-Host Cell Interactions UMI 3265 CNRS-UJF-EMBL, Grenoble, France). Since the early 80's Emmanuel Drouet focused on generation of monoclonal antibodies for biomedical purpose. He received his PhD in Clinical Virology from the Universtité Claude Bernard, Lyon, in 1991 and has been leading diagnosis and development activities at Institut Pasteur (Lyon) in the area of viral diseases (herpesviruses) since this date. Emmanuel Drouet has an excellent track record in herpesvirus field, and his group is engaged in clinical research in the field of EBV diseases. Current research included the field of Hepatitis C virus research, leading to elucidation of some aspects of its epidemiology and control. He is currently professor of virology at Grenoble University (Faculty of Pharmacy). He's member of steering committee of the master Erasmus Mundus "BioHealth Computing" recently selected by the EACEA (Education Audiovisual & Culture Executive Agency).
Professor Benoît Polack
Benoît Polack is professor in Haematology at the Medical University of Grenoble, head of the department of Haematology Oncology Genetic and Immunology of the Institute of Biology and Pathology in the University Hospital of Grenoble, and leads the laboratory Experimental Recombinant Therapy (TheREx, TIMC-IMAG, UMR CNRS 5525). After a degree in medicine in the University of Tours, he spent his internship in clinical and biological haematology in Grenoble and specialized in clinical and biological haemostasis. He was MD in 1983, PhD in 1990 and habilitated to direct research in 1996. Benoît Polack has authored or co-authored more than 90 international papers, mainly in the fields of Haemostasis and microbiology. He is member of the International Society of Thrombosis and Haemostasis, the French Society of Haematology, the French society for Biological Chemistry, the American Society for Microbiology, and the American Association for the Advancement of Science. He is reviewer for the Journal of Thrombosis and Haemostasis, Blood Coagulation and Fibrinolysis, and PLoS Pathogens, and member of the editorial board of BMC Microbiology and of the newly founded Bioengineered Bugs.